nach oben

Der Nervenarzt

Erschienen in:

01.11.2012 | Übersichten

Depression und neurologische Erkrankungen

verfasst von: Dr. D. Piber, K. Hinkelmann, S.M. Gold, C. Heesen, C. Spitzer, M. Endres, C Otte

Erschienen in: Der Nervenarzt | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei vielen neurologischen Erkrankungen ist ein depressives Syndrom charakteristisches Merkmal der Primärerkrankung oder als Komorbidität von Bedeutung. Die Post-Stroke-Depression ist beispielsweise eine häufige und relevante psychiatrische Komplikation nach einem ischämischen Hirninfarkt. Etwa 4 von 10 Schlaganfallpatienten entwickeln im Verlauf ihrer Erkrankung eine depressive Störung, die sich ungünstig auf Verlauf und Prognose auswirkt. Umgekehrt ist eine Depression jedoch auch als Risikofaktor für bestimmte neurologische Erkrankungen zu werten. So wurde kürzlich in einer Metaanalyse prospektiver Kohortenstudien ein deutlich erhöhtes Schlaganfallrisiko für depressive Patienten nachgewiesen. Ferner spielt die Depression bei weiteren neurologischen Erkrankungen eine wichtige Rolle bezüglich Verlauf und Lebensqualität, etwa beim Morbus Parkinson, der Multiplen Sklerose oder der Epilepsie. Der Artikel möchte eine Übersicht geben über die wichtigsten epidemiologischen, pathophysiologischen und therapeutischen Aspekte depressiver Störungen als Komorbidität neurologischer Erkrankungen bzw. als Risikofaktor für neurologische Erkrankungen.

Goldstein LB, Bushnell CD, Adams RJ et al (2011) Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:517–584PubMed

Loubinoux I, Kronenberg G, Endres M et al (2012) Poststroke depression: mechanisms, translation and therapy. J Cell Mol Med. DOI 10.1111/j.1582-4934.2012.01555.x

Whyte EM, Mulsant BH (2002) Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry 52:253–264PubMed

Kronenberg G, Katchanov J, Endres M (2006) Post-stroke depression: clinical aspects, epidemiology, therapy, and pathophysiology. Nervenarzt 77:1176, 1179–1182, 1184–1185PubMed

Heuschmann PU, Busse O, Wagner M et al (2010) Schlaganfallhäufigkeit und Versorgung von Schlaganfallpatienten in Deutschland. Für das Kompetenznetz Schlaganfall, die Deutsche Schlaganfall Gesellschaft sowie die Stiftung Deutsche Schlaganfall-Hilfe. Akt Neurol 37:333–340

Folstein MF, Maiberger R, McHugh PR (1977) Mood disorder as a specific complication of stroke. J Neurol Neurosurg Psychiatry 40:1018–1020PubMed

Kronenberg G, Balkaya M, Prinz V et al (2012) Exofocal dopaminergic degeneration as antidepressant target in mouse model of poststroke depression. Biol Psychiatry [Epub ahead of print]

Robinson RG, Spalletta G (2010) Poststroke depression: a review. Can J Psychiatry 55:341–349PubMed

Huff W, Steckel R, Sitzer M (2003) Poststroke depression: risk factors and effects on the course of the stroke. Nervenarzt 74:104–114PubMed

10.

Morris PL, Robinson RG, Andrzejewski P et al (1993) Association of depression with 10-year poststroke mortality. Am J Psychiatry 150:124–129PubMed

11.

Carson AJ, MacHale S, Allen K et al (2000) Depression after stroke and lesion location: a systematic review. Lancet 356:122–126PubMed

12.

Hackett ML, Anderson CS, House AO (2005) Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 36:1098–1103PubMed

13.

Boden-Albala B, Litwak E, Elkind MS et al (2005) Social isolation and outcomes post stroke. Neurology 64:1888–1892PubMed

14.

Hackett ML, Anderson CS, House A, Xia J (2008) Interventions for treating depression after stroke. Cochrane Database Syst Rev 4:CD003437PubMed

15.

Härter M, Klesse C, Bermejo I et al (2010) Evidence-based therapy of depression: S3 guidelines on unipolar depression. Nervenarzt 81:1049–1068PubMed

16.

Marcum ZA, Vande Griend JP, Linnebur SA (2012) FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 10:264–271PubMed

17.

Robinson RG, Jorge RE, Moser DJ et al (2008) Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 299:2391–2400PubMed

18.

Chollet F, Tardy J, Albucher JF et al (2011) Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 10:123–130PubMed

19.

Dam M, Tonin P, De Boni A et al (1996) Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 27:1211–1214PubMed

20.

Pariente J, Loubinoux I, Carel C et al (2001) Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 50:718–729PubMed

21.

Zittel S, Weiller C, Liepert J (2008) Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair 22:3

22.

Strubel T, Birkhofer A, Mössmer G, Förstl H (2010) SSRI – treatment and bleeding. What risks do we take? Nervenarzt 81:549–555PubMed

23.

Niedermaier N, Bohrer E, Schulte K et al (2004) Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry 65:1619–1623PubMed

24.

Neu P (2009) Correlation of depression with stroke. Pathophysiological mechanisms. Nervenarzt 80:772, 774–776, 778–780PubMed

25.

Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:e442PubMed

26.

Pan A, Sun Q, Okereke OI et al (2011) Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA 306:1241–1249PubMed

27.

Dong JY, Zhang YH, Tong J, Qin LQ (2012) Depression and risk of stroke: a meta-analysis of prospective studies. Stroke 43:32–37PubMed

28.

O’Donnell MJ, Xavier D, Liu L, Zhang H et al (2010) Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 376:112–123

29.

Whooley MA (2006) Depression and cardiovascular disease: healing the broken-hearted. JAMA 295:2874–2881PubMed

30.

Holsboer F, Ising M (2010) Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol 61:81–109, C1–11PubMed

31.

Lederbogen F, Baranyai R, Gilles M et al (2004) Effect of mental and physical stress on platelet activation markers in depressed patients and healthy subjects: a pilot study. Psychiatry Res 127:55–64PubMed

32.

Duivis HE, Jonge P de, Penninx BW et al (2011) Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am J Psychiatry 168:913–920PubMed

33.

Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732–741PubMed

34.

Otte C, Marmar CR, Pipkin SS et al (2004) Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: the Heart and Soul Study. Biol Psychiatry 56:241–247PubMed

35.

Otte C, Neylan TC, Pipkin SS et al (2005) Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry 162:2139–2145PubMed

36.

Schweiger U, Greggersen W, Rudolf S et al (2008) Disturbed glucose disposal in patients with major depression; application of the glucose clamp technique. Psychosom Med 70:170–176PubMed

37.

Whooley MA, Jonge P de, Vittinghoff E, Otte C et al (2008) Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 300:2379–2388PubMed

38.

Win S, Parakh K, Eze-Nliam CM et al (2011) Depressive symptoms, physical inactivity and risk of cardiovascular mortality in older adults: the Cardiovascular Health Study. Heart 97:500–505PubMed

39.

Gehi A, Haas D, Pipkin S, Whooley MA (2005) Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med 165:2508–2513PubMed

40.

Thorndike AN, Regan S, McKool K et al (2008) Depressive symptoms and smoking cessation after hospitalization for cardiovascular disease. Arch Intern Med 168:186–191PubMed

41.

Glassman AH, O’Connor CM, Califf RM et al (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288:701–709PubMed

42.

Lange-Asschenfeldt C, Lederbogen F (2011) Antidepressant therapy in coronary artery disease. Nervenarzt 82:657–664PubMed

43.

O’Connor CM, Jiang W, Kuchibhatla M et al (2008) Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 168:2232–2237

44.

Taylor CB, Youngblood ME, Catellier D et al (2005) Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 62:792–798PubMed

45.

Honkola J, Hookana E, Malinen S et al (2012) Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J 33:745–751PubMed

46.

Smoller JW, Allison M, Cochrane BB et al (2009) Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women’s Health Initiative study. Arch Intern Med 169:2128–2139PubMed

47.

Hamer M, David Batty G, Seldenrijk A, Kivimaki M (2011) Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. Eur Heart J 32:437–442PubMed

48.

Lichtman JH, Bigger JT Jr, Blumenthal JA et al (2008) Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 118:1768–1775PubMed

49.

Rijk MC de, Launer LJ, Berger K et al (2000) Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 (Suppl 5):21–23

50.

Aarsland D, Marsh L, Schrag A (2009) Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord 24:2175–2186PubMed

51.

Aarsland D, Ballard C, Walker Z et al (2009) Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8:613–618PubMed

52.

Seppi K, Weintraub D, Coelho M et al (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):42–80

53.

Aarsland D, Påhlhagen S, Ballard CG et al (2011) Depression in Parkinson disease – epidemiology, mechanisms and management. Nat Rev Neurol 8:35–47PubMed

54.

Reijnders JS, Ehrt U, Weber WE et al (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189PubMed

55.

Barone P et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649PubMed

56.

Riedel O, Dodel R, Deuschl G et al (2011) Dementia and depression determine care dependency in Parkinson’s disease: analysis of 1,449 outpatients receiving nursing care in Germany. Nervenarzt 82:1012–1019PubMed

57.

Ishihara L, Brayne C (2006) A systematic review of depression and mental illness preceding Parkinson’s disease. Acta Neurol Scand 113:211–220PubMed

58.

Schwarz J, Odin P, Buhmann C et al (2011) Depression in Parkinson’s disease. J Neurol 258 (Suppl 2):336–338

59.

Nanhoe-Mahabier W et al (2009) Parkinson disease and comorbid cerebrovascular disease. Nat Rev Neurol 5:533–541PubMed

60.

Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580PubMed

61.

Skapinakis P et al (2010) Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol 10:49PubMed

62.

Richard IH, McDermott MP, Kurlan R et al (2012) A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78:1229–1236PubMed

63.

Weintraub D, Burn DJ (2011) Parkinson’s disease: the quintessential neuropsychiatric disorder. Mov Disord 26:1022–1031PubMed

64.

Dobkin RD, Allen LA, Menza M (2007) Cognitive-behavioral therapy for depression in Parkinson’s disease: a pilot study. Mov Disord 22:946–952PubMed

65.

Farabaugh A et al (2010) Cognitive-behavioral therapy for patients with Parkinson’s disease and comorbid major depressive disorder. Psychosomatics 51:124–129PubMed

66.

Feinstein A (2006) Mood disorders in multiple sclerosis and the effects on cognition. J Neurol Sci 245:63–66PubMed

67.

D’Alisa S, Miscio G, Baudo S et al (2006) Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study. Disabil Rehabil 28:307–314

68.

Bruce JM, Hancock LM, Arnett P, Lynch S (2010) Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med 33:219–227PubMed

69.

Feinstein A (2002) An examination of suicidal intent in patients with multiple sclerosis. Neurology 59:674–678PubMed

70.

Goldman (2005) The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 11:328–337

71.

Siegert RJ, Abernethy DA (2005) Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 76:469–475PubMed

72.

Patten SB, Beck CA, Williams JV et al (2003) Major depression in multiple sclerosis: a population-based perspective. Neurology 61:1524–1527PubMed

73.

Schiffer RB, Wineman NM, Weitkamp LR (1986) Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry 143:94–95PubMed

74.

Feinstein A (2011) Multiple sclerosis and depression. Mult Scler 17:1276–1281PubMed

75.

Feinstein A, O’Connor P, Feinstein K (2002) Multiple sclerosis, interferon beta-1b and depression. A prospective investigation. J Neurol 249:815–820PubMed

76.

Bakshi R, Czarnecki D, Shaikh ZA et al (2000) Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport 11:1153–1158PubMed

77.

Bakshi R, Shaikh ZA, Miletich RS et al (2000) Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 6:181–185PubMed

78.

Feinstein A, Roy P, Lobaugh N et al (2004) Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 62:586–590PubMed

79.

Zorzon M, Masi R de, Nasuelli D et al (2001) Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol 248:416–421PubMed

80.

Zorzon M, Zivadinov R, Nasuelli D et al (2002) Depressive symptoms and MRI changes in multiple sclerosis. Eur J Neurol 9:491–496PubMed

81.

Gold SM, Kern KC, O’Connor MF et al (2010) Smaller cornu ammonis 2–3 – dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol Psychiatry 68:553–559PubMed

82.

Kiy G, Lehmann P, Hahn HK et al (2011) Decreased hippocampal volume, indirectly measured, is associated with depressive symptoms and consolidation deficits in multiple sclerosis. Mult Scler 17:1088–1097PubMed

83.

Fassbender K, Schmidt R, Mossner R et al (1998) Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch Neurol 55:66–72PubMed

84.

Gold SM, Kruger S, Ziegler KJ et al (2011) Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry 82:814–818PubMed

85.

Kern S, Schultheiss T, Schneider H et al (2011) Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis. Psychoneuroendocrinology 36:1505–1512PubMed

86.

Pokryszko-Dragan A, Frydecka I, Kosmaczewska A et al (2012) Stimulated peripheral production of interferon-gamma is related to fatigue and depression in multiple sclerosis. Clin Neurol Neurosurg [Epub ahead of print]

87.

Fischer A, Otte C, Krieger T et al (2012) Decreased hydrocortisone sensitivity of T cell function in multiple sclerosis-associated major depression. Psychoneuroendocrinology [Epub ahead of print]

88.

Pakenham KI (1999) Adjustment to multiple sclerosis: application of a stress and coping model. Health Psychol 18:383–392PubMed

89.

Feinstein A (2005) The clinical neuropsychiatry of multiple sclerosis. CNS Spectr 10:362PubMed

90.

Koch MW, Glazenborg A, Uyttenboogaart M et al (2011) Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev 2:CD007295PubMed

91.

Mohr DC, Hart SL, Julian L et al (2005) Telephone-administered psychotherapy for depression. Arch Gen Psychiatry 62:1007–1014PubMed

92.

Grossman P, Kappos L, Gensicke H et al (2010) MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology 75:1141–1149PubMed

93.

Mostert JP, Admiraal-Behloul F, Hoogduin JM et al (2008) Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry 79:1027–1031PubMed

94.

Sijens PE, Mostert JP, Irwan R et al (2008) Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. Psychiatry Res 164:274–282PubMed

95.

Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139–1151PubMed

96.

Stenager EN, Stenager E, Koch-Henrikson N et al (1992) Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry 55:542–545PubMed

97.

Stenager EN, Koch-Henriksen N, Stenager E (1996) Risk factors for suicide in multiple sclerosis. Psychother Psychosom 65:86–90PubMed

98.

Fuller-Thomson E, Brennenstuhl S (2009) The association between depression and epilepsy in a nationally representative sample. Epilepsia 50:1051–1058PubMed

99.

Mensah SA, Beavis JM, Thapar AK, Kerr MP (2007) A community study of the presence of anxiety disorder in people with epilepsy. Epilepsy Behav 11:118–124PubMed

100.

Canuet L, Ishii R, Iwase M et al (2009) Factors associated with impaired quality of life in younger and older adults with epilepsy. Epilepsy Res 83:58–65PubMed

101.

Harris EC, Barraclough B (1997) Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 170:205–228PubMed

102.

Nilsson L, Tomson T, Farahmand BY et al (1997) Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia 38:1062–1068PubMed

103.

Christensen J, Vestergaard M, Mortensen PB et al (2007) Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 6:693–698PubMed

104.

Bell GS, Sander JW (2009) Suicide and epilepsy. Curr Opin Neurol 22:174–178PubMed

105.

Hoppe C, Elger CE (2011) Depression in epilepsy: a critical review from a clinical perspective. Nat Rev Neurol 7:462–472PubMed

106.

Hermann BP, Trenerry MR, Colligan RC (1996) Learned helplessness, attributional style, and depression in epilepsy. Bozeman Epilepsy Surgery Consortium. Epilepsia 37:680–686PubMed

107.

Wagner JL, Smith G, Ferguson PL et al (2009) A hopelessness model of depressive symptoms in youth with epilepsy. J Pediatr Psychol 34:89–96PubMed

108.

Hesdorffer DC, Lee P (2009) Health, wealth, and culture as predominant factors in psychosocial morbidity. Epilepsy Behav 15:36–40

109.

Sperling MR, Schilling CA, Glosser D et al (2008) Self-perception of seizure precipitants and their relation to anxiety level, depression, and health locus of control in epilepsy. Seizure 17:302–307PubMed

110.

Kanner AM, Trimble M, Schmitz B (2010) Postictal affective episodes. Epilepsy Behav 19:156–158PubMed

111.

Hughes JR (2010) Periodic lateralized epileptiform discharges: do they represent an ictal pattern requiring treatment? Epilepsy Behav 18:162–165PubMed

112.

Mula M, Monaco F (2009) Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord 11:1–9PubMed

113.

Miller JM, Kustra RP, Vuong A et al (2008) Depressive symptoms in epilepsy: prevalence, impact, aetiology, biological correlates and effect of treatment with antiepileptic drugs. Drugs 68:1493–1509PubMed

114.

Danzer SC (2012) Depression, stress, epilepsy and adult neurogenesis. Exp Neurol 233:22–32PubMed

115.

Micallef S, Spooner CG, Harvey AS et al (2010) Psychological outcome profiles in childhood-onset temporal lobe epilepsy. Epilepsia 51:2066–2073PubMed

116.

Barry JJ, Ettinger AB, Friel P et al (2008) Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav 13(Suppl 1):1–29

117.

Bernardo CG, Singh V, Thompson PM (2008) Safety and efficacy of psychopharmacological agents used to treat the psychiatric sequelae of common neurological disorders. Expert Opin Drug Saf 7:435–445PubMed

118.

Ekinci O, Titus JB, Rodopman AA et al (2009) Depression and anxiety in children and adolescents with epilepsy: prevalence, risk factors, and treatment. Epilepsy Behav 14:8–18PubMed

119.

Thompson NJ et al (2010) Distance delivery of mindfulness-based cognitive therapy for depression: project UPLIFT. Epilepsy Behav 19:247–254PubMed

120.

Walker ER, Obolensky N, Dini S, Thompson NJ (2010) Formative and process evaluations of a cognitive-behavioral therapy and mindfulness intervention for people with epilepsy and depression. Epilepsy Behav 19:239–246PubMed

121.

Ciechanowski P et al (2010) PEARLS depression treatment for individuals with epilepsy: a randomized controlled trial. Epilepsy Behav 19:225–231PubMed

122.

Wagner JL, Smith G, Ferguson P et al (2010) Pilot study of an integrated cognitive-behavioral and self-management intervention for youth with epilepsy and caregivers: Coping Openly and Personally with Epilepsy (COPE). Epilepsy Behav 18:280–285PubMed

123.

DiIorio C, Shafer PO, Letz R et al (2004) Project EASE study group. Project EASE: a study to test a psychosocial model of epilepsy medication managment. Epilepsy Behav 5:926–936PubMed

124.

Chaytor N, Ciechanowski P, Miller JW et al (2011) Long-term outcomes from the PEARLS randomized trial fort he treatment of depression in patients with epilepsy. Epilepsy Behav 20:545–549PubMed

125.

Lundgren T, Dahl J, Yardi N, Melin L (2008) Acceptance and commitment therapy and yoga for drug-refractory epilepsy: a randomized controlled trial. Epilepsy Behav 13:102–108PubMed

126.

Lundgren T, Dahl J, Hayes SC (2008) Evaluation of mediators of change in the treatment of epilepsy with acceptance and commitment therapy. J Behav Med 31:225–235PubMed

127.

Martinovic Z, Simonovic P, Djokic R (2006) Preventing depression in adolescents with epilepsy. Epilepsy Behav 9:619–624PubMed

128.

Arida RM, Scorza FA, Cavalheiro EA (2010) Favorable effects of physical activity for recovery in temporal lobe epilepsy. Epilepsia 51:76–79PubMed

129.

Arida RM, Scorza FA, Silva SG da et al (2010) The potential role of physical exercise in the treatment of epilepsy. Epilepsy Behav 17:432–435PubMed

130.

Kanner AM (2011) Depression and epilepsy: a bidirectional relation? Epilepsia 52:21–27PubMed

131.

Cotterman-Hart S (2010) Depression in epilepsy: why aren’t we treating? Epilepsy Behav 19:419–421PubMed

Titel: Depression und neurologische Erkrankungen
verfasst von: Dr. D. Piber
K. Hinkelmann
S.M. Gold
C. Heesen
C. Spitzer
M. Endres
C Otte
Publikationsdatum: 01.11.2012
Verlag: Springer-Verlag
Erschienen in: Der Nervenarzt / Ausgabe 11/2012
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-012-3674-7

Neu in den Fachgebieten Neurologie und Psychiatrie

25.04.2024 | Hypotonie | Nachrichten

Springer Medizin

Depression und neurologische Erkrankungen

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2012

Psychoonkologie

Mitteilungen der DGN 11/2012

Achtsamkeitsbasierte Psychotherapie

PSYCHOSOMATIK

Peripartale Depressionen und Trauer nach Schwangerschaftsverlusten

Schmerzverarbeitung bei psychiatrischen Erkrankungen

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet